Diagnostic Value of Serum Cytokeratin 18 for the Staging of Liver Inflammation and Fibrosis: A Meta‐Analysis
Journal of Clinical Laboratory Analysis · 2025
DOI: 10.1002/jcla.70034 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Clinical Laboratory Analysis, 2025. Verfasst von Jinwen Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai Hospital, Zhuhai, China. Hauptthemen laut MEDLINE: Hepatitis, Keratin-18, Liver Cirrhosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhuhai medical research project.
Abstract (Originalsprache)
Background and Aims Accurate assessment of liver inflammation and fibrosis is of vital importance in the clinical management of patients with liver diseases. Our aim is to conduct a meta‐analysis to evaluate the diagnostic accuracy of serum cytokeratin 18 (CK18) for staging of liver inflammation and fibrosis against a liver biopsy in adults.
Methods
We systematically searched articles from eight electronic databases. Two authors independently selected included studies, extracted data, and assessed quality. In our meta‐analysis, we used the random‐effects meta‐analysis model. Publication bias, sensitivity analysis, heterogeneity analysis, and post‐test probability were used in this meta study.
Results
A total of 20 studies with 2235 patients were initially found by the search strategies. The pooled sensitivity, specificity, and area under the curve (AUC) of the summary receiver operating characteristic curve were 0.56, 0.81, and 0.810 for significant fibrosis; 0.64, 0.76, and 0.785 for advanced fibrosis; 0.53, 0.76, and 0.830 for cirrhosis; and 0.68, 0.73, and 0.786 for significant inflammation, respectively. High heterogeneity was observed in our meta‐analysis because of factors such as the proportion of males, total number, and antigens of CK‐18.
Conclusion
Serum CK18 had moderate diagnostic value (AUC > 0.7) in different stages of liver fibrosis and significant inflammation, offering a complementary approach to other non‐invasive indicators such as serological biomarkers and imaging techniques. Future research should focus on elucidating the role of CK18 in the occurrence and progression of hepatitis and liver fibrosis, particularly in liver diseases with diverse etiologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai Hospital, Zhuhai, China.
- School of Automation, Guangdong University of Technology, Guangzhou, China.
- Zhuhai Seesheen Medical Technology Company Limited, Zhuhai, China.
- Medical Research Center, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China.
ORCID-Profile: Se Peng, Xiaoting Huang, Jialing Zhuang
Förderung
- Zhuhai medical research project
Zitieren
APA
Chen, J., Hu, J., Zhuang, J., Li, Z., Peng, S., Huang, X., & Zhuang, J. (2025). Diagnostic Value of Serum Cytokeratin 18 for the Staging of Liver Inflammation and Fibrosis: A Meta‐Analysis. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70034
Vancouver
Chen J, Hu J, Zhuang J, Li Z, Peng S, Huang X, et al. Diagnostic Value of Serum Cytokeratin 18 for the Staging of Liver Inflammation and Fibrosis: A Meta‐Analysis. Journal of Clinical Laboratory Analysis. 2025. doi:10.1002/jcla.70034
BibTeX
@article{Chen2025,
author = {Chen, Jinwen and Hu, Jian and Zhuang, Jialin and Li, Zhong and Peng, Se and Huang, Xiaoting and Zhuang, Jialing},
title = {Diagnostic Value of Serum Cytokeratin 18 for the Staging of Liver Inflammation and Fibrosis: A Meta‐Analysis},
journal = {Journal of Clinical Laboratory Analysis},
year = {2025},
doi = {10.1002/jcla.70034}
}
EUVIMED